Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC (INSIGHT 2)
NCT03940703Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Sep 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Sep 2019; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03940703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940703.